Loading people...
Debra Liebert is a Managing Director at Domain Associates, a prominent life sciences venture capital firm based in San Diego, California. At Domain Associates, a firm that has raised more than two billion dollars in capital, she helps manage a portfolio that has completed 305 investments and 90 exits across the biotechnology and medical device sectors. Before her current role, Liebert served as Executive Director of New Product Management at CancerVax Corporation and held Vice President of Corporate Development positions at Trega Biosciences and LPL Technologies. She also founded multiple therapeutic companies, including Calixa Therapeutics and Sonexa Therapeutics, and served as an Independent Non-Executive Director at Milestone Pharmaceuticals from 2015 to 2024. Holding a Master of Business Administration from UCLA, Liebert focuses her career on advancing early-stage healthcare innovation and guiding therapeutic companies through multiple development stages.
Debra K. Liebert stands as a vital investor at Domain Associates, a distinguished venture capital firm renowned for its deep expertise and significant contributions to the life sciences industry. In her capacity, Debra is instrumental in the firm's mission to discover, fund, and nurture groundbreaking companies that are poised to revolutionize healthcare and biotechnology. Her work involves a meticulous evaluation of emerging technologies, therapeutic platforms, and medical devices, ensuring that Domain Associates invests in ventures with the highest potential for both scientific impact and market success.
Domain Associates has a long-standing reputation for its commitment to the life sciences, and Debra K. Liebert's role aligns perfectly with this specialized focus. She actively seeks out opportunities in areas such as biopharmaceuticals, medical technology, diagnostics, and digital health, always with an eye towards innovation that addresses unmet medical needs. Her strategic insights help guide portfolio companies through critical development stages, from initial research and development to clinical trials and market entry.
While specific details of Debra K. Liebert's career background prior to Domain Associates are not widely publicized, it is common for investors in such specialized fields to possess a robust foundation in science, medicine, or the pharmaceutical industry. This background would provide her with the necessary technical understanding and industry acumen to effectively assess complex scientific proposals and market dynamics. Her expertise likely encompasses a blend of scientific knowledge, business development skills, and a keen understanding of the regulatory landscape within healthcare.
At Domain Associates, the collective investment strategy often involves early-stage and growth-stage funding for companies developing novel drugs, therapies, and medical devices. While individual notable investments directly attributed to Debra K. Liebert are not publicly detailed, her contributions are integral to the firm's overall success in backing companies that have gone on to achieve significant milestones, including successful clinical outcomes, regulatory approvals, and strategic acquisitions. Her dedication helps ensure that Domain Associates continues to be a driving force in bringing life-saving and life-improving innovations to patients worldwide. Through her diligent work, Debra K. Liebert reinforces Domain Associates' position as a leader in life sciences venture capital.
Debra K. Liebert is an investor at Domain Associates, a prominent venture capital firm specializing in the life sciences sector. She plays a key role in identifying and supporting innovative companies in healthcare and biotechnology.
Debra K. Liebert, through Domain Associates, invests in companies within the life sciences sector. This includes areas such as biopharmaceuticals, medical technology, diagnostics, and digital health, focusing on innovations that address critical medical needs.
Debra K. Liebert works at Domain Associates, a leading venture capital firm with a dedicated focus on investing in and developing companies within the life sciences industry.
